Published in Mol Pharm on July 15, 2011
AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer (OVERT-1) | NCT00610714
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer (2013) 1.93
The clinical relevance of cancer cell lines. J Natl Cancer Inst (2013) 1.54
Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol (2013) 1.29
Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. PLoS One (2012) 1.08
Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. Cancer Res (2012) 0.95
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin Cancer Res (2012) 0.94
MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor. Blood (2013) 0.92
Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity. Cancer (2013) 0.90
Prediction of resistance to chemotherapy in ovarian cancer: a systematic review. BMC Cancer (2015) 0.85
CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma. Mol Cancer (2015) 0.81
The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene. J Natl Cancer Inst (2015) 0.81
Integrative analyses of genetic variation, epigenetic regulation, and the transcriptome to elucidate the biology of platinum sensitivity. BMC Genomics (2014) 0.80
A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy. Mol Pharmacol (2015) 0.77
A 10-gene expression signature of Notch pathway predicts recurrence in ovarian carcinoma. Oncol Lett (2015) 0.76
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Cancer of the ovary. N Engl J Med (2004) 11.21
Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst (2003) 9.68
Anoikis resistance and tumor metastasis. Cancer Lett (2008) 2.90
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
Mechanisms of multidrug resistance in cancer. Methods Mol Biol (2010) 2.25
Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst (2010) 1.89
Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther (2009) 1.83
Abcb10 physically interacts with mitoferrin-1 (Slc25a37) to enhance its stability and function in the erythroid mitochondria. Proc Natl Acad Sci U S A (2009) 1.82
Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol (2003) 1.75
Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett (2009) 1.68
Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res (2004) 1.58
Lymphatic drainage of the peritoneal cavity and its significance in ovarian cancer. Am J Obstet Gynecol (1974) 1.52
Clustering of the SOM easily reveals distinct gene expression patterns: results of a reanalysis of lymphoma study. BMC Bioinformatics (2002) 1.48
Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res (2001) 1.41
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res (2006) 1.38
Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res (1999) 1.31
Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3. Mol Cancer Ther (2005) 1.28
Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. Biochem J (1999) 1.26
Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line. Biochem Biophys Res Commun (2003) 1.25
Slc2a5 (Glut5) is essential for the absorption of fructose in the intestine and generation of fructose-induced hypertension. J Biol Chem (2008) 1.25
TIMP-1 as a tumor marker in breast cancer--an update. Acta Oncol (2008) 1.20
Tumor classification and marker gene prediction by feature selection and fuzzy c-means clustering using microarray data. BMC Bioinformatics (2003) 1.13
P-glycoprotein: so many ways to turn it on. J Clin Pharmacol (2007) 1.11
Transport of drugs by proton-coupled peptide transporters: pearls and pitfalls. Expert Opin Drug Metab Toxicol (2009) 1.10
Profiling studies in ovarian cancer: a review. Oncologist (2007) 1.09
Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. Cancer Res (2001) 1.08
Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival. Biochem J (2003) 1.07
Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis (2010) 1.07
Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): a novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian endoscopy study group on colorectal cancer detection. Scand J Gastroenterol (2008) 1.06
A new framework for identifying combinatorial regulation of transcription factors: a case study of the yeast cell cycle. J Biomed Inform (2007) 1.06
The peroxisomal ABC transporter family. Pflugers Arch (2006) 1.05
Human ATP-binding cassette transporter TaqMan low-density array: analysis of macrophage differentiation and foam cell formation. Clin Chem (2006) 1.02
Diagnostic problems in serous effusions. Diagn Cytopathol (1998) 1.02
Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. J Biol Chem (2002) 1.01
The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol (2001) 1.01
The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer. Gynecol Oncol (2009) 1.00
Biological characteristics of cancers involving the serosal cavities. Crit Rev Oncog (2007) 1.00
Role and relevance of PEPT2 in drug disposition, dynamics, and toxicity. Drug Metab Pharmacokinet (2008) 0.95
Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. Cancer (2008) 0.95
Reaction intermediates in the catalytic mechanism of Escherichia coli MutY DNA glycosylase. J Biol Chem (2004) 0.93
Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase. Cancer Chemother Pharmacol (2004) 0.92
Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients. Gynecol Oncol (2005) 0.89
Inference of gene regulatory networks using boolean-network inference methods. J Bioinform Comput Biol (2009) 0.87
Importance of glutathione and associated enzymes in drug response. Oncol Res (1997) 0.87
GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing. Oncogene (2006) 0.87
Overexpression of aldo-keto reductase 1C2 is associated with disease progression in patients with prostatic cancer. Histopathology (2010) 0.84
Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions. Clin Exp Metastasis (2002) 0.82
Expression of the major fas family and Bcl-2 family of proteins in epithelial ovarian cancer (EOC) and their correlation to chemotherapeutic response and outcome. Oncol Res (2010) 0.80
A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science (2006) 15.18
Targeting multidrug resistance in cancer. Nat Rev Drug Discov (2006) 10.55
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res (2008) 3.98
Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell (2004) 3.72
P-glycoprotein: from genomics to mechanism. Oncogene (2003) 3.66
Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer (2005) 3.26
Hotspots of transcription factor colocalization in the genome of Drosophila melanogaster. Proc Natl Acad Sci U S A (2006) 3.06
Notch3 gene amplification in ovarian cancer. Cancer Res (2006) 2.66
MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One (2008) 2.60
CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res (2012) 2.57
DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther (2009) 2.53
Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. Genome Biol (2003) 2.52
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest (2010) 2.32
Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev (2012) 2.31
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A (2005) 2.29
Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res (2008) 2.26
The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol (2008) 2.26
Mechanisms of multidrug resistance in cancer. Methods Mol Biol (2010) 2.25
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res (2007) 2.15
Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol (2005) 2.07
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res (2008) 2.04
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res (2007) 1.91
Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst (2010) 1.89
Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res (2004) 1.89
Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther (2009) 1.83
Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima. J Mol Biol (2008) 1.80
A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta (2009) 1.79
Calculating confidence intervals for prediction error in microarray classification using resampling. Stat Appl Genet Mol Biol (2008) 1.70
Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res (2006) 1.64
Silent (synonymous) SNPs: should we care about them? Methods Mol Biol (2009) 1.61
CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics (2009) 1.58
Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res (2010) 1.55
The clinical relevance of cancer cell lines. J Natl Cancer Inst (2013) 1.54
Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat (2012) 1.53
Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas. Cancer Res (2007) 1.53
A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci U S A (2006) 1.52
VAMP2-dependent exocytosis regulates plasma membrane insertion of TRPC3 channels and contributes to agonist-stimulated Ca2+ influx. Mol Cell (2004) 1.49
Expression of E-cadherin transcriptional regulators in ovarian carcinoma. Virchows Arch (2006) 1.49
Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res (2010) 1.48
Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Res (2003) 1.48
The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci (2010) 1.46
Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol (2008) 1.46
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos (2008) 1.46
Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol (2010) 1.45
The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. Biochemistry (2006) 1.45
Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos (2010) 1.41
Array comparative genomic hybridization reveals distinct DNA copy number differences between gastrointestinal stromal tumors and leiomyosarcomas. Cancer Res (2006) 1.41
Functional characterization of Candida albicans ABC transporter Cdr1p. Eukaryot Cell (2003) 1.40
Identification of novel mutations by exome sequencing in African American colorectal cancer patients. Cancer (2014) 1.39
Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell Melanoma Res (2009) 1.38
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med (2013) 1.38
Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci (2009) 1.37
Fine-needle aspiration cytology vs. core biopsy in the diagnosis of breast lesions. Diagn Cytopathol (2003) 1.36
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci U S A (2012) 1.35
Catalytic cycle of ATP hydrolysis by P-glycoprotein: evidence for formation of the E.S reaction intermediate with ATP-gamma-S, a nonhydrolyzable analogue of ATP. Biochemistry (2007) 1.35
Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer (2010) 1.35
High resolution detection and analysis of CpG dinucleotides methylation using MBD-Seq technology. PLoS One (2011) 1.35
Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol (2002) 1.35
Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat (2012) 1.35
Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res (2011) 1.34
Human ABCB6 localizes to both the outer mitochondrial membrane and the plasma membrane. Biochemistry (2007) 1.33
Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol (2008) 1.32
Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biol Ther (2006) 1.32
Aneuploidy-dependent massive deregulation of the cellular transcriptome and apparent divergence of the Wnt/beta-catenin signaling pathway in human rectal carcinomas. Cancer Res (2006) 1.31
SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol Cancer Res (2008) 1.30
Mutational analysis of ABCG2: role of the GXXXG motif. Biochemistry (2004) 1.29
Laminin-induced signaling in tumor cells: the role of the M(r) 67,000 laminin receptor. Cancer Res (2004) 1.28
Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther (2008) 1.28
High recombination rates and hotspots in a Plasmodium falciparum genetic cross. Genome Biol (2011) 1.27
About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work. Mol Cancer Ther (2007) 1.27
Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc Natl Acad Sci U S A (2010) 1.25
Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther (2004) 1.24
A dual-fluorescence high-throughput cell line system for probing multidrug resistance. Assay Drug Dev Technol (2009) 1.22
Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res (2005) 1.22
Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol Cancer Ther (2008) 1.22
Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. Cancer (2004) 1.22
Laminin-induced signaling in tumor cells. Cancer Lett (2005) 1.21